Effects of Modified Qing'e Pill (sic) on expression of adiponectin, bone morphogenetic protein 2 and coagulation-related factors in patients with nontraumatic osteonecrosis of femoral head
Effects of Modified Qing'e Pill (sic) on expression of adiponectin, bone morphogenetic protein 2 and coagulation-related factors in patients with nontraumatic osteonecrosis of femoral head
复制标题
DOI：
10.1007/s11655-016-2407-3
复制
发表时间：
2017-03-01
影响因子：
2.9
通讯作者：
Ma, Chen
中科院分区：
文献类型：
--
作者：
Li, Cheng-gang;Shen, Lin;Ma, Chen
观察加味青娥丸的调节作用（原文如此，MQEP），对脂联素、骨形态发生蛋白2（BMP 2）、将96例非创伤性股骨头坏死（ONFH）患者随机分为治疗组和对照组，每组10例对照组36例。治疗组采用MQEP治疗，对照组采用模拟药丸治疗。两组均给予钙尔奇D。6个月为1个疗程。每2个月随访一次。治疗前后检测血浆脂联素、骨形态发生蛋白2（BMP 2）、骨保护素（OPG）、血管性血友病因子（vWF）、血管性血友病因子裂解蛋白酶（vWF-cp）、纤溶酶原激活物抑制物1（派-1）、组织型纤溶酶原激活物（tPA）、C反应蛋白（CRP）、血液流变学、股骨头骨密度（BMD）及Harris髋关节评分。与对照组比较，治疗组脂联素、BMP 2水平显著升高（P < 0.01和P=0.013），vWF、派-1和CRP水平显著降低（P=0.019，P < 0.01和P < 0.01），血液流变学指标显著降低。治疗组股骨颈、三角区骨密度及Harris髋关节评分均显著高于对照组。血浆脂联素水平与骨形态发生蛋白2呈正相关（r=0.231，P=0.003），与纤溶酶原激活物抑制剂1呈负相关（r=-0.159，P < 0.05），MQEP可能通过增加脂联素的表达，调节骨代谢，改善高凝状态，对非创伤性股骨头坏死具有保护作用，为其临床疗效提供实验依据。
To observe the regulation of Chinese herbal medicine, Modifified Qing'e Pill (sic, MQEP), on the expression of adiponectin, bone morphogenetic protein 2 (BMP2), osteoprotegerin (OPG) and other potentially relevant risk factors in patients with nontraumatic osteonecrosis of the femoral head (ONFH).A total of 96 patients with nontraumatic ONFH were unequal randomly divided into treatment group (60 cases) and control group (36 cases). The treatment group were treated with MQEP while the control group were treated with simulated pills. Both groups were given caltrate D. Six months were taken as a treatment course. Patients were followed up every 2 months. The levels of plasma adiponectin, BMP2, OPG, von Willebrand factor (vWF), von Willebrand factor cleaving protease (vWF-cp), plasminogen activator inhibitor 1 (PAI-1), tissue plasminogen activator (tPA), C-reactive protein (CRP), blood rheology, bone mineral density (BMD) of the femoral head and Harris Hip Score were measured before and after treatment.After 6 months of treatment, compared with the control group, patients in the treatment group had signifificantly higher adiponectin and BMP2 levels (P < 0.01 and P=0.013, respectively), lower vWF, PAI-1 and CRP levels (P=0.019, P < 0.01 and P < 0.01, respectively), and lower blood rheology parameters. BMD of the femoral neck, triangle area and Harris Hip Score in the treatment group were signifificantly higher than those in the control group. Moreover, plasma adiponectin showed a positive association with BMP2 (r=0.231, P=0.003) and a negative association with PAI-1 (r=-0.159, P < 0.05).MQEP may play a protective role against nontraumatic ONFH by increasing the expression of adiponectin, regulating bone metabolism and improving the hypercoagulation state, which may provide an experimental base for its clinical effects.